Roflumilast Cream as First‑Line Therapy for Atopic Dermatitis

FDA Approval and Indications

The American Academy of Dermatology notes that roflumilast cream 0.15 % is FDA‑approved for mild‑to‑moderate atopic dermatitis in patients ≥ 6 years, and a 0.05 % formulation is approved for children 2–5 years old【1】.

In phase‑2 trials, treatment‑related adverse events occurred in only 2.2 % of patients using roflumilast cream, with application‑site pain or stinging reported in ≤ 0.5–2.1 % across all age groups【1】.
The 52‑week open‑label extension showed that only 4.7 % of adverse events were deemed treatment‑related, confirming a favorable long‑term safety profile【1】.
Systemic absorption of roflumilast cream is minimal and does not produce immunosuppressive effects【1】.
Roflumilast carries no black‑box warning and has no theoretical malignancy or immunosuppression concerns【1】.

The American Academy of Dermatology recommends initiating roflumilast cream 0.15 % once daily for the first 4 weeks; once clear (vIGA‑AD 0), patients should switch to proactive twice‑weekly application to flare‑prone areas, with continuous use possible for up to 56 weeks【1】.

The 2025 AAD guidelines assign a strong recommendation to roflumilast cream as the preferred first‑line topical agent for mild‑to‑moderate atopic dermatitis【1】.

The American Academy of Dermatology gives tacrolimus a strong recommendation based on high‑quality evidence for atopic dermatitis, but it is approved only as second‑line therapy for moderate‑to‑severe disease when other topicals have failed or are inadvisable【2】.
Tacrolimus 0.1 % (adults) or 0.03 % (children 2–15 years) should be used short‑term or intermittently, with counseling about the FDA black‑box warning and theoretical malignancy concerns【2】.
Tacrolimus may still be appropriate for patients who are already successfully maintained on it without adverse effects【2】.

In facial and intertriginous areas where corticosteroid‑induced atrophy is a concern and roflumilast is not tolerated, tacrolimus can be considered【3】【4】.

Tacrolimus should not be used in patients with severely impaired skin‑barrier function (e.g., Netherton syndrome)【5】【6】.

Combining tacrolimus with phototherapy is discouraged because of a theoretical increased risk of epithelial tumors【7】.